Sonoma Pharmaceuticals (SNOA) Raw Materials (2012 - 2025)

Sonoma Pharmaceuticals' Raw Materials history runs 13 years deep, the most recent figure standing at $2.1 million for Q4 2025.

• On a quarterly basis, Raw Materials rose 50.29% year-over-year to $2.1 million in Q4 2025; TTM through Dec 2025 was $2.1 million, a 50.29% increase from a year earlier, with the FY2025 full-year figure at $1.4 million, down 22.59% from the prior year.
• Raw Materials rose to $2.1 million in Q4 2025 per SNOA's latest filing, from $2.0 million in the prior quarter.
• Across five years, Raw Materials topped out at $2.1 million in Q4 2025 and bottomed at $1.4 million in Q4 2024.
• The 5-year median for Raw Materials is $1.6 million (2021), against an average of $1.7 million.
• Across the five-year window, Raw Materials slumped 40.81% in 2021 and soared 50.29% in 2025, its largest moves.
• Year by year, Raw Materials stood at $1.6 million in 2021, then dropped by 0.98% to $1.6 million in 2022, then slipped by 6.46% to $1.5 million in 2023, then declined by 8.69% to $1.4 million in 2024, then surged by 50.29% to $2.1 million in 2025.
• Per Business Quant, the three latest SNOA Raw Materials figures stand at $2.1 million (Q4 2025), $2.0 million (Q3 2025), and $1.8 million (Q2 2025).